Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Transgenic mouse models that independently express mutations in amyloid precursor protein (APP) and tau have proven useful for the study of the neurological consequences of amyloid-beta (Abeta) plaque and neurofibrillary tangle pathologies. Studies using these mice have yielded essential discoveries with regard to specific aspects of neuronal dysfunction and degeneration that characterize the brain during Alzheimer's disease (AD) and other age-dependent tauopathies. Most recent transgenic studies have focused on the creation of regulatable models that allow the temporal control of transgene expression. To study a more complete model of AD pathology, we designed a new regulatable transgenic mouse that harbors both APP and tau transgenes. Here, we present a novel transgenic mouse model, rTg3696AB, which expresses human APP(NLI) and tau(P301L) driven by the CaMKII promoter system. Subsequent generation of Abeta and 4R0N tau in the brain resulted in the development of three neuropathological features of AD: Abeta plaques, neurofibrillary tangles, and neurodegeneration. Importantly, transgene expression in these mice is regulatable, permitting temporal control of gene expression and the investigation of transgene suppression.

[1]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[2]  H. Bujard,et al.  The Potential for β-Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy , 2008, The Journal of Neuroscience.

[3]  M. Staufenbiel,et al.  Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice , 2007 .

[4]  L. Mucke,et al.  Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.

[5]  B. Hyman,et al.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. , 2006, The American journal of pathology.

[6]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[7]  J. Ávila,et al.  Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation , 2005, Neuroscience.

[8]  I. Ferrer,et al.  Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice , 2005, Neurobiology of Disease.

[9]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[10]  H. Lester,et al.  Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease , 2005, PLoS medicine.

[11]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[12]  P. T. Nguyen,et al.  Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy , 2005, The Journal of Neuroscience.

[13]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[14]  F. van Leuven,et al.  Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice* , 2005, Journal of Biological Chemistry.

[15]  D. Holtzman,et al.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. , 2005, The Journal of clinical investigation.

[16]  D. Selkoe,et al.  Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases , 2004, Nature Cell Biology.

[17]  Edward A. Stern,et al.  Cortical Synaptic Integration In Vivo Is Disrupted by Amyloid-β Plaques , 2004, The Journal of Neuroscience.

[18]  Gregory A. Hickey,et al.  Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations , 2003, The Journal of Neuroscience.

[19]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[20]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[21]  Kazuki Sato,et al.  Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  B. Hyman,et al.  In Vivo Multiphoton Imaging of a Transgenic Mouse Model of Alzheimer Disease Reveals Marked Thioflavine‐S‐Associated Alterations in Neurite Trajectories , 2003, Journal of neuropathology and experimental neurology.

[23]  H. E. Stanley,et al.  Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[25]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[26]  J. Lucas,et al.  FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain , 2001, Molecular and Cellular Neuroscience.

[27]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[28]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[29]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[30]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[31]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[32]  M. Hasselmo,et al.  Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[34]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[36]  E. Kandel,et al.  Control of Memory Formation Through Regulated Expression of a CaMKII Transgene , 1996, Science.

[37]  D L Price,et al.  A vector for expressing foreign genes in the brains and hearts of transgenic mice. , 1996, Genetic analysis : biomolecular engineering.

[38]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[39]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[40]  J. Hardy,et al.  A locus for familial early–onset Alzhelmer's disease on the long arm of chromosome 14, proximal to the α1–antichymotrypsin gene , 1992, Nature Genetics.

[41]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[43]  Kimberly Scearce-Levie,et al.  Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. , 2007, The Journal of biological chemistry.

[44]  M. Staufenbiel,et al.  Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. , 2007, The American journal of pathology.

[45]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[46]  P. Keller,et al.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.

[47]  Brian J Bacskai,et al.  Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  Kazuki Sato,et al.  Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Bitan,et al.  Amyloid (cid:1) -Protein Oligomerization PRENUCLEATION INTERACTIONS REVEALED BY PHOTO-INDUCED CROSS-LINKING OF UNMODIFIED PROTEINS* , 2001 .

[50]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.